# REGENERON PHARMACEUTICALS, INC. (REGN) FY2025 Annual Balance Sheet

- Company: REGENERON PHARMACEUTICALS, INC. (REGN)
- Period: As of 2025-12-31
- Filing: FY2025 10-K, filed 2026-02-04, accession number 0000872589-26-000008
- Page: https://plicit.ai/financials/regn/fy2025-annual-balance-sheet
- Chart image: https://plicit.ai/charts/regn-fy2025-annual-balance-sheet-sankey.png

## Chart details

Balance sheet as of 2025-12-31. The chart shows assets, liabilities and equity at that date.

- **Assets**: 40,558,700,000 US dollars
- **Current assets**: 18,021,900,000 US dollars
- **Non-current assets**: 22,536,800,000 US dollars
- **Liabilities**: 9,301,800,000 US dollars
- **Current liabilities**: 4,368,400,000 US dollars
- **Non-current liabilities**: 4,933,400,000 US dollars
- **Equity**: 31,256,900,000 US dollars
- **Accounts receivable, net**: 5,741,100,000 US dollars
- **Marketable securities**: 5,487,100,000 US dollars
- **Inventories**: 3,200,800,000 US dollars
- **Cash and cash equivalents**: 3,118,100,000 US dollars
- **Prepaid expenses and other current assets**: 474,800,000 US dollars
- **Marketable securities**: 10,260,600,000 US dollars
- **Property, plant, and equipment, net**: 5,120,400,000 US dollars
- **Deferred tax assets**: 4,077,200,000 US dollars
- **Other noncurrent assets**: 1,821,200,000 US dollars
- **Intangible assets, net**: 1,257,400,000 US dollars
- **Accrued expenses and other current liabilities**: 2,876,400,000 US dollars
- **Accounts payable**: 939,000,000 US dollars
- **Deferred revenue**: 553,000,000 US dollars
- **Other noncurrent liabilities**: 2,018,800,000 US dollars
- **Long-term debt**: 1,985,900,000 US dollars
- **Finance lease liabilities**: 720,000,000 US dollars
- **Deferred revenue**: 208,700,000 US dollars
- **Retained earnings**: 35,797,100,000 US dollars
- **Additional paid-in capital**: 13,995,000,000 US dollars
- **Accumulated other comprehensive income (loss)**: 77,500,000 US dollars
- **Common stock - Common Stock**: 100,000 US dollars
- **Preferred Stock, par value $.01 per share; 30.0 shares authorized; shares issued and outstanding - none**: 0 US dollars
- **Common stock - Class A Stock**: 0 US dollars
- **Treasury Stock, at cost; 33.7 shares in 2025 and 28.2 shares in 2024**: negative 18,612,800,000 US dollars
- **Gross equity (calculated)**: 49,869,700,000 US dollars. Net equity plus the magnitudes of its negative contributions equals gross positive equity. The negative contributions enter this reconciliation as add-backs; their filed signs stay negative.

### Chart connections

- Assets equal liabilities plus consolidated equity. Consolidated equity includes noncontrolling interests when reported.
- Treasury shares and other negative equity contributions reduce equity.